AU2004210975B2 - Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers - Google Patents

Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers Download PDF

Info

Publication number
AU2004210975B2
AU2004210975B2 AU2004210975A AU2004210975A AU2004210975B2 AU 2004210975 B2 AU2004210975 B2 AU 2004210975B2 AU 2004210975 A AU2004210975 A AU 2004210975A AU 2004210975 A AU2004210975 A AU 2004210975A AU 2004210975 B2 AU2004210975 B2 AU 2004210975B2
Authority
AU
Australia
Prior art keywords
protein
antibody
cell
cancer
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004210975A
Other languages
English (en)
Other versions
AU2004210975A1 (en
Inventor
Pia M. Challita-Eid
Mary Faris
Wangmao Ge
Jean Gudas
Aya Jakobovits
Steven B. Kanner
Karen Jane Meyrick Morrison
Robert Kendall Morrison
Juan J. Perez-Villar
Arthur B. Raitano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of AU2004210975A1 publication Critical patent/AU2004210975A1/en
Application granted granted Critical
Publication of AU2004210975B2 publication Critical patent/AU2004210975B2/en
Priority to AU2008203053A priority Critical patent/AU2008203053B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004210975A 2003-02-10 2004-02-10 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers Expired AU2004210975B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008203053A AU2008203053B2 (en) 2003-02-10 2008-07-10 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44663303P 2003-02-10 2003-02-10
US60/446,633 2003-02-10
PCT/US2004/003984 WO2004072263A2 (en) 2003-02-10 2004-02-10 Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008203053A Division AU2008203053B2 (en) 2003-02-10 2008-07-10 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

Publications (2)

Publication Number Publication Date
AU2004210975A1 AU2004210975A1 (en) 2004-08-26
AU2004210975B2 true AU2004210975B2 (en) 2008-04-10

Family

ID=32869540

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2004210975A Expired AU2004210975B2 (en) 2003-02-10 2004-02-10 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
AU2008203053A Expired AU2008203053B2 (en) 2003-02-10 2008-07-10 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
AU2010201615A Expired AU2010201615B2 (en) 2003-02-10 2010-04-22 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2008203053A Expired AU2008203053B2 (en) 2003-02-10 2008-07-10 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
AU2010201615A Expired AU2010201615B2 (en) 2003-02-10 2010-04-22 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

Country Status (6)

Country Link
EP (2) EP1594892A2 (OSRAM)
JP (3) JP2007524361A (OSRAM)
AU (3) AU2004210975B2 (OSRAM)
CA (2) CA2515699C (OSRAM)
IL (1) IL170080A (OSRAM)
WO (1) WO2004072263A2 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501741D0 (en) * 2005-01-27 2005-03-02 Binding Site The Ltd Antibody
EP1840133A1 (en) * 2006-03-29 2007-10-03 Global Biotech Development Corp. Ltd. New immunomodulating oligopeptides
CN101448849B (zh) * 2006-03-31 2013-08-21 阿尔尼拉姆医药品有限公司 抑制Eg5基因表达的组合物和方法
JP2013179911A (ja) * 2012-03-02 2013-09-12 Dainippon Printing Co Ltd 電極付き細胞試験具の接続装置、及びそれを用いた細胞試験装置
AR092219A1 (es) * 2012-08-23 2015-04-08 Seattle Genetics Inc Conjugados anticuerpo-farmaco (adc) que se unen a proteinas 158p1d7
EP3579872A1 (en) * 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
JPWO2023105976A1 (OSRAM) * 2021-12-08 2023-06-15

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016593A2 (en) * 2000-08-22 2002-02-28 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
WO2002020569A2 (en) * 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
WO2002059377A2 (en) * 2001-01-24 2002-08-01 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5359100A (en) 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DK0462145T3 (da) 1989-03-07 1994-08-08 Genentech Inc Covalente konjugater mellem lipid og oligonucleotid
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
WO1991006309A1 (en) 1989-11-03 1991-05-16 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
AU8221191A (en) 1990-06-27 1992-01-23 Princeton University Probes for detecting mutant p53
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
CA2141960A1 (en) 1992-08-07 1994-02-17 Ralph T. Kubo Hla binding peptides and their uses
EP0703783B1 (en) 1993-03-05 2010-05-05 Epimmune Inc. Methods of making immunogenic hla-a2.1 binding peptides
CA2163129A1 (en) 1993-05-17 1994-11-24 Flossie Wong-Staal Ribozyme gene therapy for hiv infection and aids
US5837501A (en) 1993-07-09 1998-11-17 Akzo Nobel N.V. Nucleic acid quantitation by co-amplification of target with multiple internal controls
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
US5681697A (en) 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1996002561A1 (en) 1994-07-20 1996-02-01 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
JPH11502717A (ja) 1995-04-11 1999-03-09 ザ ジェネラル ホスピタル コーポレーション 逆ツーハイブリッドシステム
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
ATE511849T1 (de) 1996-03-11 2011-06-15 Epimmune Inc Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle
ATE224454T1 (de) 1996-04-26 2002-10-15 Massachusetts Inst Technology Drei hybriden screening test
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
CA2271234C (en) 1996-10-15 2011-04-26 The Regents Of The University Of California Animal models of human prostate cancer progression
US6365797B1 (en) 1997-10-15 2002-04-02 The Regents Of The University Of California Mice models of human prostate cancer progression
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
HUP0300595A3 (en) * 2000-04-27 2007-06-28 Smithkline Beecham Corp Novel compounds
WO2002026826A2 (en) * 2000-09-27 2002-04-04 Curagen Corporation Proteins and nucleic acids encoding same
WO2003102155A2 (en) * 2002-06-03 2003-12-11 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
KR102028770B1 (ko) 2011-09-15 2019-10-04 컨버전트 인포메이션 테크놀로지스 게엠베하 로봇 프로그램의 자동 생성을 위한 시스템 및 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016593A2 (en) * 2000-08-22 2002-02-28 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
WO2002020569A2 (en) * 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
WO2002059377A2 (en) * 2001-01-24 2002-08-01 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer

Also Published As

Publication number Publication date
JP2015057068A (ja) 2015-03-26
EP2343315A3 (en) 2011-11-23
AU2008203053B2 (en) 2010-02-18
JP2011200233A (ja) 2011-10-13
EP2343315A2 (en) 2011-07-13
WO2004072263A3 (en) 2004-12-23
AU2010201615A1 (en) 2010-05-13
JP2007524361A (ja) 2007-08-30
AU2008203053A1 (en) 2008-07-31
CA2515699A1 (en) 2004-08-26
IL170080A (en) 2015-03-31
CA2515699C (en) 2015-01-27
AU2004210975A1 (en) 2004-08-26
CA2860151A1 (en) 2004-08-26
EP1594892A2 (en) 2005-11-16
AU2010201615B2 (en) 2012-08-16
WO2004072263A2 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
AU2002361610B2 (en) Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7250498B2 (en) Nucleic acids and corresponding proteins entitled 273P4B7 useful in treatment and detection of cancer
US8951744B2 (en) Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
AU2002361610A1 (en) Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
AU2010226920A1 (en) Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US6863892B2 (en) Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
AU2004235755A1 (en) Nucleic acids and corresponding proteins entitled 109P1D4 useful in treatment and detection of cancer
AU2010201615B2 (en) Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
AU2007201445A1 (en) Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer
CA2514058A1 (en) Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
US7811575B2 (en) Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer
CA2588564A1 (en) Nucleic acids and corresponding proteins entitled 158p3d2 useful in treatment and detection of cancer
CA2496566A1 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
AU2007216892B2 (en) Nucleic acids and corresponding proteins entitled 273P4B7 useful in treatment and detection of cancer
AU2002258688A1 (en) Nucleic acid and corresponding protein entitled 238p1b2 useful in treatment and detection of cancer

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO COMPLY WITH SECTION 6(C) HAS BEEN EXTENDED TO 25 SEP 2004.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired